Shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) were down 4.8% during mid-day trading on Friday . The stock traded as low as $0.61 and last traded at $0.60. Approximately 924,926 shares traded hands during mid-day trading, an increase of 0% from the average daily volume of 920,980 shares. The stock had previously closed at $0.63.

Separately, Maxim Group reaffirmed a “buy” rating and issued a $4.00 price target on shares of ContraVir Pharmaceuticals in a report on Thursday, August 24th.

The company’s market cap is $48.36 million. The stock’s 50 day moving average is $0.53 and its 200-day moving average is $0.77.

An institutional investor recently raised its position in ContraVir Pharmaceuticals stock. Vanguard Group Inc. increased its position in ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 17.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,414,475 shares of the biopharmaceutical company’s stock after purchasing an additional 366,192 shares during the quarter. Vanguard Group Inc. owned approximately 3.79% of ContraVir Pharmaceuticals worth $1,400,000 at the end of the most recent quarter. Institutional investors and hedge funds own 10.27% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/10/08/contravir-pharmaceuticals-inc-ctrv-shares-down-4-8.html.

ContraVir Pharmaceuticals Company Profile

ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100.

Receive News & Stock Ratings for ContraVir Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.